avapro has been researched along with Innate Inflammatory Response in 26 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 6.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| " Adiponectin exerts strong protection against a number of pathological events by suppressing cell death, inhibiting inflammation, and enhancing cell survival, while leptin promotes inflammation, oxidative stress, atherogenesis, and thrombosis." | 4.12 | Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes. ( Hattori, N; Matsuda, T; Nakatsuji, S; Nishiyama, N; Shimatsu, A; Yamada, A, 2022) |
| "Treatment with irbesartan attenuates cardiac inflammation in type 2 diabetic db/db mice, and this effect was probably associated with the suppression of cardiac angiotensin II and NF-κB signaling pathway." | 3.83 | [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice]. ( Gong, WQ; Huang, WC; Liang, Y; Liu, B; Yang, CM; Ye, XL; Zheng, YT, 2016) |
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 2.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| "Seventy patients with symptomatic carotid artery stenosis were randomized to irbesartan (300 mg/d) or chlorthalidone (50 mg/d) for 4 months before endarterectomy." | 2.71 | Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. ( Bei, R; Bucci, M; Cipollone, F; Cuccurullo, C; Cuccurullo, F; de Cesare, D; De Luca, M; Fazia, M; Iezzi, A; Mezzetti, A; Muraro, R; Pini, B; Spigonardo, F; Ucchino, S; Zucchelli, M, 2004) |
| "The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction." | 2.71 | Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. ( Cheema, FA; Khan, BV; Khan-Merchant, N; Menon, RG; Mir, MQ; Parthasarathy, S; Sola, S, 2005) |
| "The reduction in cytokine levels in the atheroma supernatant was correlated to a reduction in ERK1/2 expression in the tissue." | 1.40 | Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. ( Clancy, P; Golledge, J; Koblar, SA, 2014) |
| "Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of a metabolic syndrome characterized by accumulation of hepatic fat, inflammation and varying degrees of fibrosis." | 1.38 | Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. ( Kato, J; Kishina, M; Koda, M; Matono, T; Murawaki, Y; Sugihara, T; Tokunaga, S; Ueki, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Hattori, N | 1 |
| Yamada, A | 1 |
| Nakatsuji, S | 1 |
| Matsuda, T | 1 |
| Nishiyama, N | 1 |
| Shimatsu, A | 1 |
| Gao, J | 1 |
| Liang, Z | 1 |
| Zhao, F | 1 |
| Liu, X | 1 |
| Ma, N | 1 |
| Arab, HH | 1 |
| Eid, AH | 1 |
| El-Sheikh, AAK | 1 |
| Arafa, EA | 1 |
| Ashour, AM | 1 |
| Yang, Q | 1 |
| Yu, J | 1 |
| Qin, H | 1 |
| Liu, L | 1 |
| Di, C | 1 |
| Zhuang, Q | 1 |
| Yin, H | 1 |
| Ye, XL | 1 |
| Huang, WC | 1 |
| Zheng, YT | 1 |
| Liang, Y | 1 |
| Gong, WQ | 1 |
| Yang, CM | 1 |
| Liu, B | 1 |
| Boccellino, M | 1 |
| Di Domenico, M | 1 |
| Donniacuo, M | 1 |
| Bitti, G | 1 |
| Gritti, G | 1 |
| Ambrosio, P | 1 |
| Quagliuolo, L | 1 |
| Rinaldi, B | 1 |
| Georgescu, A | 1 |
| Alexandru, N | 1 |
| Nemecz, M | 1 |
| Titorencu, I | 1 |
| Popov, D | 1 |
| Hartner, A | 1 |
| Cordasic, N | 1 |
| Klanke, B | 1 |
| Menendez-Castro, C | 1 |
| Veelken, R | 1 |
| Schmieder, RE | 1 |
| Hilgers, KF | 1 |
| Zhao, Y | 3 |
| Watanabe, A | 2 |
| Zhao, S | 2 |
| Kobayashi, T | 1 |
| Fukao, K | 2 |
| Tanaka, Y | 1 |
| Nakano, T | 2 |
| Yoshida, T | 1 |
| Takemoto, H | 1 |
| Tamaki, N | 2 |
| Kuge, Y | 2 |
| Clancy, P | 1 |
| Koblar, SA | 1 |
| Golledge, J | 1 |
| Hamada, T | 1 |
| Yamasaki, K | 1 |
| Shimizu, Y | 1 |
| Kubo, N | 1 |
| Ukon, N | 1 |
| Xing, G | 1 |
| Wei, M | 1 |
| Xiu, B | 1 |
| Ma, Y | 1 |
| Liu, T | 1 |
| Persson, F | 2 |
| Rossing, P | 2 |
| Hovind, P | 2 |
| Stehouwer, CD | 2 |
| Schalkwijk, CG | 1 |
| Tarnow, L | 2 |
| Parving, HH | 2 |
| Russell, JC | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Krone, W | 1 |
| Hanefeld, M | 1 |
| Meyer, HF | 1 |
| Jung, T | 1 |
| Bartlett, M | 1 |
| Yeh, CM | 1 |
| Rajman, I | 1 |
| Prescott, MF | 1 |
| Dole, WP | 1 |
| Yang, H | 1 |
| Nyby, MD | 1 |
| Ao, Y | 1 |
| Chen, A | 1 |
| Adelson, DW | 1 |
| Smutko, V | 1 |
| Wijesuriya, J | 1 |
| Go, VL | 1 |
| Tuck, ML | 1 |
| Ma, C | 1 |
| Lu, XC | 1 |
| Fan, L | 1 |
| Luo, Y | 1 |
| Yang, B | 1 |
| Gao, Y | 1 |
| Liu, XF | 1 |
| Kato, J | 1 |
| Koda, M | 1 |
| Kishina, M | 1 |
| Tokunaga, S | 1 |
| Matono, T | 1 |
| Sugihara, T | 1 |
| Ueki, M | 1 |
| Murawaki, Y | 1 |
| Cipollone, F | 1 |
| Fazia, M | 1 |
| Iezzi, A | 1 |
| Pini, B | 1 |
| Cuccurullo, C | 1 |
| Zucchelli, M | 1 |
| de Cesare, D | 1 |
| Ucchino, S | 1 |
| Spigonardo, F | 1 |
| De Luca, M | 1 |
| Muraro, R | 1 |
| Bei, R | 1 |
| Bucci, M | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Lou, M | 1 |
| Blume, A | 1 |
| Gohlke, P | 1 |
| Deuschl, G | 1 |
| Herdegen, T | 1 |
| Culman, J | 1 |
| Schieffer, B | 1 |
| Bünte, C | 1 |
| Witte, J | 1 |
| Hoeper, K | 1 |
| Böger, RH | 1 |
| Schwedhelm, E | 1 |
| Drexler, H | 1 |
| Sola, S | 1 |
| Mir, MQ | 1 |
| Cheema, FA | 1 |
| Khan-Merchant, N | 1 |
| Menon, RG | 1 |
| Parthasarathy, S | 1 |
| Khan, BV | 1 |
| Ceriello, A | 1 |
| Assaloni, R | 1 |
| Da Ros, R | 1 |
| Maier, A | 1 |
| Piconi, L | 1 |
| Quagliaro, L | 1 |
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Schalkwijk, C | 1 |
| Westermann, D | 1 |
| Rutschow, S | 1 |
| Jäger, S | 1 |
| Linderer, A | 1 |
| Anker, S | 1 |
| Riad, A | 1 |
| Unger, T | 1 |
| Schultheiss, HP | 1 |
| Pauschinger, M | 1 |
| Tschöpe, C | 1 |
| Tousoulis, D | 1 |
| Kourtellaris, P | 1 |
| Antoniades, C | 1 |
| Vasiliadou, C | 1 |
| Papageorgiou, N | 1 |
| Tentolouris, C | 1 |
| Siasos, G | 1 |
| Stefanadi, E | 1 |
| Stefanadis, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)[NCT00317915] | Phase 3 | 0 participants | Interventional | Completed | |||
| Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| Relation Between Postprandial Lipogram and Coronary Artery Disease Severity[NCT03175393] | 100 participants (Anticipated) | Observational | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for avapro and Innate Inflammatory Response
| Article | Year |
|---|---|
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Topics: Adult; Aged; Albuminuria; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2008 |
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Cardiovascular Dise | 2011 |
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2004 |
Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphe | 2004 |
Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Biomarkers; Biphenyl Compounds; Brachi | 2005 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, | 2005 |
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type | 2006 |
Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Flow Velocity; Coronary Disease; E-Selectin; Enzy | 2008 |
18 other studies available for avapro and Innate Inflammatory Response
| Article | Year |
|---|---|
Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; | 2022 |
Triptolide inhibits oxidative stress and inflammation via the microRNA-155-5p/brain-derived neurotrophic factor to reduce podocyte injury in mice with diabetic nephropathy.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Diabetes Mellitus; Diabetic Nephropathies; Di | 2022 |
Irbesartan reprofiling for the amelioration of ethanol-induced gastric mucosal injury in rats: Role of inflammation, apoptosis, and autophagy.
Topics: AMP-Activated Protein Kinases; Angiotensin Receptor Antagonists; Animals; Anti-Inflammatory Agents; | 2022 |
Irbesartan suppresses lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC.
Topics: Actomyosin; Animals; Behavior, Animal; Blood-Brain Barrier; Capillary Permeability; Cell Line; Depre | 2021 |
[Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].
Topics: Actins; Angiotensin II; Animals; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Exp | 2016 |
AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress.
Topics: Animals; Cardiovascular Diseases; Catalase; Gene Expression Regulation; Heart Injuries; Humans; Hypo | 2018 |
Irbesartan administration therapeutically influences circulating endothelial progenitor cell and microparticle mobilization by involvement of pro-inflammatory cytokines.
Topics: Animals; Arteries; Atherosclerosis; Biphenyl Compounds; Cell Adhesion; Cell-Derived Microparticles; | 2013 |
Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Blood Glucose; Bloo | 2014 |
Suppressive effects of irbesartan on inflammation and apoptosis in atherosclerotic plaques of apoE-/- mice: molecular imaging with 14C-FDG and 99mTc-annexin A5.
Topics: Analysis of Variance; Animals; Annexin A5; Apolipoproteins E; Apoptosis; Autoradiography; Azo Compou | 2014 |
Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Com | 2014 |
Irbesartan attenuates atherosclerosis in Watanabe heritable hyperlipidemic rabbits: noninvasive imaging of inflammation by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Autoradiography; Biphenyl Compounds; Body Weight; | 2015 |
[Irbesartan reduces inflammatory response of central nervous system in a rat model of fluid percussion brain injury].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Brain; Brain Injuries; Carbon | 2016 |
Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiovascular Diseases; Infla | 2009 |
Role of brainstem thyrotropin-releasing hormone-triggered sympathetic overactivation in cardiovascular mortality in type 2 diabetic Goto-Kakizaki rats.
Topics: Adrenal Glands; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; | 2012 |
[Irbesartan regulates inflammatory gene expressions related to atherosclerosis in EA.hy926 cells].
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Cell Line; Cytoprotect | 2011 |
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Comp | 2012 |
Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Brain; Brain Ischem | 2004 |
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomyopathies; Collagen Typ | 2007 |